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Abstract
Introduction: In the recent years, much attention has been paid to the use of leukotriene receptor antagonists (LTRA) 
in the treatment of bronchial asthma (BA). It has been even proposed to use them as alternatives to hormone therapy. 
Yet, there are studies demonstrating the advantage of montelukast as similar to placebo. The objective was to create a 
methodology for determining the correlation of the clinical efficacy of therapy with the addition of a drug (on example, 
clinical efficacy of montelukast in an anti-asthmatic therapy in pediatric patients).
Materials and methods: The data on prescribed regimens was retrospectively extracted from the inpatient records 
of 608 BA patients admitted to hospital in 2014–2015. Mathematical evaluation was based on the risk factor concept.
Results and discussion: The absolute efficacies (AEs) was estimated to be 91.85% (95% CI 90.15–93.55%) in the 
exposed group; the attributable efficacy (AtE) was found to be 17.00% (95% CI 10.91–23.09%); the relative efficacy 
(RE) was found to be 1.23 (95% CI 0.21–2.24); and the population attributable efficacy (PAtE) was found to be 7.55% 
(95% CI 2.49–12.61%).
Conclusions: The AtE, RE, and PAtE were statistically significant. The RE was found to be 1.23. However, the lower lim-
it of its 95% CI (0.21–2.24) was less than 1, indicating that the increase in clinical efficacy was not found to be statistically 
significant. In the studied sample positive outcome rates were 91.85% (95% CI 90.15–93.55%) in the exposed group and 
74.85% (95% CI 72.49–77.21%) in the comparator group. He presented methodology for determining the correlation of 
the clinical efficacy of the pharmacotherapy regimen with the addition of a drug can be successfully applied in the future.
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Introduction
Bronchial asthma (BA) is a common inflammatory di-
sease of respiratory tract in children. Recent years have 
shown a worldwide increasing trend in incidence rates 
and severity of BA, as well as its earlier manifestation.
Substantial progress in treating BA was achieved when 
background therapy was introduced, which reduced chro-
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nic allergic inflammation in bronchi and thus decreased 
a risk of bronchial obstruction and irreversible structural 
changes in the bronchial wall. The BA background thera-
py include inhaled glucocorticosteroids (IGCSs), systemic 
glucocorticosteroids (GCSs), leukotriene receptor antago-
nists (LTRAs), long-acting β2-agonists (LABAs) in combi-
nation with IGCSs, cromones (cromoglicic acid and sodium 
nedocromil), sustained-release theophyllines, and anti-IgE 
antibodies (GLOBAL INITIATIVE FOR ASTHMA 2016).
Treatment of severe refractory BA is a pressing pro-
blem. Patients with severe BA need high doses of com-
bined drugs (IGCSs and LABAs) or, in case of their inef-
ficacy, systemic GCSs.
Recently, the use of LTRAs in BA has taken a lot of at-
tention. They have been suggested to be used as an alter-
native to hormonal agents (Ciółkowski et al. 2016, Hon et 
al. 2014). Studies show a high degree of clinical efficacy 
of LTRAs in pediatric BA patients (Stelmach et al. 2015). 
However, some studies have shown that montelukast is 
as effective as placebo (Joos et al. 2008). No study has 
shown statistical superiority of montelukast over IGCS 
(Castro-Rodriguez and Rodrigo 2010). A guideline on 
the management of acute BA attacks in children by the 
Italian Society of Pediatricians does not recommend the 
use of montelukast as a standard therapy for BA attacks 
(Indinnimeo et al. 2018). The recommendation is based 
on a Cochrane Library review that did not demonstrate a 
statistically significant difference in hospitalization risks 
after using oral montelukast in addition to the standard 
regimen (Watts and Chavasse 2012). Recent studies have 
supported this conclusion (Wang et al. 2018).
The objective of this study was to analyze the mathema-
tical correlation between the addition of montelukast to an 
anti-asthmatic therapy in children and its clinical efficacy.
Materials and methods
The data on prescribed regimens was retrospectively ex-
tracted from case records of 608 BA patients, undergoing 
inpatient treatment in a Nizhniy Novgorod healthcare fa-
cility from 2014 to 2015.
The following drugs and their combinations were used 
as asthma control medications in the facility during the 
time-frame of the study: (1) IGCSs alone; (2) a combina-
tion of IGCS and short-acting β2-agonists (SABA); (3) a 
combination of IGCS and LABA; (4) a combination of 
IGCS and LTRA; (5) a combination of IGCS, SABA, and 
LTRA; (6) a combination of SABA and LTRA; (7) ) a 
combination of IGCS, LABA, and LTRA.
To determine the mathematical correlation between the 
clinical efficacy of an anti-asthmatic therapy and adding 
montelukast to it, absolute numbers of positive and negative 
outcomes were determined for each treatment. The numbers 
were, respectively, 122 and 60 for IGCS, 54 and 15 for IGCS 
+ SABA, 77 and 10 for IGCS + LABA, 35 and 4 for SABA 
+ LTRA, 85 and 7 for IGCS + LTRA, 64 and 5 for IGCS + 
SABA + LTRA, and 64 and 6 for IGCS + LABA + LTRA.
A positive outcome was defined as improvement 
in a patient’s health at the time of discharge from hos-
pital achieved by using the initially prescribed regimen 
without an increase in doses and without adding any new 
medication. An outcome was defined as negative if a new 
medication, such as Euphylline, systemic GCS, etc., was 
added to the initially prescribed regimen or if the initial 
dosage or frequency was increased.
To study the correlation between the clinical efficacy 
of the addition of montelukast to an anti-asthmatic regi-
men in children, the absolute efficacies in exposed and 
unexposed groups, attributable efficacy, relative efficacy, 
and population attributable efficacy were determined al-
ong with standard errors and confidence intervals for each 
efficacy estimate. The concept of determining clinical 
efficacy was based on the concept of risk factors. This 
concept successfully used in health care (Maksimov et al. 
2010, Zhukova et al. 2015, Zhukova et al. 2017).
Results and discussion
Statistical correlation between the clinical efficacy of an 
anti-asthmatic regimen and addition of montelukast to it 
was analyzed by estimating the absolute efficacies in pa-
tients receiving or by estimating the attributable efficacy, 
the relative efficacy, and the population attributive effica-
cy in patients not receiving montelukast as a component of 
anti-asthmatic therapy, as well as by determining standard 
errors and confidence intervals for each type of efficacy.
At the first step in the analysis of statistical correlation 
between the presence of montelukast in the regimen and 
its efficacy, a contingency table (Table 1) was constructed. 
Rows and columns are arranged in a way to make sure the 
calculated parameters could be correctly interpreted.
The first row shows the group of patients that received 
montelukast-containing regimen. The second row shows 
the group of patients that did not receive montelukast. 
Thus, the first group was a test group, which received the 
drug of interest. The second group was a reference group 
to be used for efficacy comparisons. Likewise, the first 
column shows the number of cases where the event in 
question (positive clinical outcome) was recorded in the 
first and second groups, and the second column shows the 
number of cases where the event did not occur.
After constructing the contingency table, a statistical 
hypothesis was formulated on the assumption that mon-
telukast added to an anti-asthmatic regimen increased 
the rate of positive outcomes in BA, obviating the need 
to change treatment, to increase the dose, or to add new 
drugs. The first parameter, absolute efficacy (AE), was 
Table 1. Contingency Table
Montelukast in anti-
asthmatic therapy
Positive clinical outcome Total
Yes No
Yes 248 (а) 22 (b) 270 (A)
No 253 (с) 85 (d) 338 (B)
Total 501 (C) 107 (D) 608 (Q)
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calculated as a proportion of cases with positive outco-
mes out of the total number of outcomes in patients taking 
regimen with montelukast. In other words, AE was the 
rate of positive clinical outcomes in the groups of patient 
receiving or not receiving montelukast as a component 
of the anti-asthmatic regimen. Equation (1) was used to 
calculate the rate of positive clinical outcomes in the ex-
posed group (patients receiving montelukast in the regi-
men), AE was estimated to be 91.85%.
                                                                          
А
аAEe                                                                (1)
Thus, 0.9185 (91.85%) of the exposed group had posi-
tive clinical outcomes. Likewise, Eq. (2) was used to esti-
mate the rate of positive clinical outcomes in the unexpo-
sed group (patients not receiving montelukast) at 74.85% 
(absolute efficacy in the comparator group (AEu)).
                                       
В
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Point estimates were thus obtained for the favorable clini-
cal outcome rate as dependent on whether montelukast was 
added to the anti-asthmatic regimen (exposed and compara-
tor patient groups). The rates were not estimated for the total 
populations, but only for their representative samples, which 
approximately reflected the population properties. Such 
point estimates are prone to statistical errors. Standard errors 
were therefore calculated for the AE estimates to characteri-
ze the estimation accuracy. The standard error of the AE of 
the exposed group calculated from Eq. (3) was 0.017.
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where n is the size of the exposed or unexposed group, 
that is, A or B.
The standard error of the AE was similarly estimated at 
0.024 for the unexposed group.
Because different rates might be obtained using other 
samples, the extent of potential differences and the mi-
nimum intervals were estimated that cover actual point 
estimates, that is, the minimum intervals wherein the rate 
estimates fall with a probability of 95%. This interval is 
known as the 95% confidence interval (95% CI) in statis-
tics. In practice, this means that 95% of potential samples 
have the rate estimates that fall within the 95% CI, while 
only 5% of all rate estimates are beyond the 95% CI. The 
95 or 99% CI is commonly used in studies (Eq. (4)).
StAECI AE  ,  (4)
where t is the critical value of statistical significance (t = 
1.96 for 95% CI), and S is the standard error of AE.
So, 95% CI in the exposed group ranges from a lowest 
88.59% to a highest 95.12% with the mean AEe being 
91.85% and the standard error – 1.70%. Thus, a monte-
lukast-containing anti-asthmatic regimen ensured positive 
outcomes in 91.85 ± 1.70% of cases in the exposed group.
Similar calculations with Eq. (4) yielded a 95% CI of 
0.7485±0.0236 (or 74.85±2.36%) for AE of the compara-
tor group.
The AE estimates obtained for the patient groups recei-
ving or not receiving montelukast showed that montelukast 
increased the favorable clinical outcome rate. Next, in order 
to estimate how substantial was the contribution of monte-
lukast to this increase, the attributable efficacy (AtE) was 
calculated, which characterizes the proportion of efficacy 
that is associated with and accounted for by the study drug. 
AtE was estimated from Eq. (5) to be 0.1700, or 17.00%.
В
с
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Thus, the probability of positive clinical outcome was 
91.85% in the montelukast-treated group and 74.85% in 
the group that had not received montelukast. The AtE was 
17.00% in that case; i.e., montelukast increased the proba-
bility of the event in question (positive clinical outcome) 
by 17.00%.
To estimate the standard error of the difference, a poo-
led estimate of the proportion was obtained from Eq. (6) 
to be 0.8240.
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The standard error of AtE was estimated from Eq. (7) 
to be 0.0311 (or 3.11%).
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After that, 95% CI of the AtE was estimated to be 
10.91–23.09%.
Thus, montelukast as a component of an anti-asthmatic 
regimen increased the likelihood of a positive clinical out-
come in children with BA by 17.00±6.09%. So, possible 
(true) AE values falling within 95% CI indicate that AEe 
> AEu; i.e., montelukast made favorable clinical outco-
mes of anti-asthmatic therapy more likely.
Clinical efficacy estimates are based on statistics 
(mean, error of the mean, and CI), which, in turn, are ba-
sed on the probability theory. Like in the CI analysis of 
attributable efficacy, CIs are important to consider for all 
efficacy estimates. For instance, the CIs of AEe and AEu 
calculated earlier (88.59–95.12% and 70.23–79.48%, res-
pectively) do not include 0 or negative values and can, 
therefore, be deemed statistically significant.
Basing on the AtE estimate, montelukast was shown to 
increase the likelihood of a favorable clinical outcome by 
17.00% on average.
The relative efficacy (RE) was calculated to assess the 
strength of the association between drug exposure and 
outcome, characterizing how many times the efficacy of 
anti-asthmatic therapy increased due to adding monteluk-
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ast. The AEe/AEu ratio is higher than 1 when the clinical 
efficacy is higher in the exposed group, it is lower than 1 
if the clinical efficacy is lower in the exposed group, and 
it is equal to 1 when the clinical efficacy is the same in the 
two groups. Mathematical calculations showed that the 
clinical efficacy ratio in the two groups is higher than 1.
The RE was estimated to be 1.23 from Eq. (8):
В
с
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Thus, montelukast added to the anti-asthmatic regimen 
resulted in a 1.23–time increase in clinical efficacy. The 
result was tested for significance because the calculations 
were performed for the sample. The standard error of RE 
was calculated for this purpose from Eq. (9) and was 0.0364.
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The 95% CI of the RE was obtained from Eq. (10):
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The obtained range of RE with 95% CI was 0.21–2.24. 
Likewise AtE, possible (true) values falling within 95% 
CI are interpreted as follows. RE > 1 indicates that the 
drug improves clinical efficacy. When RE = 1, the drug 
does not affect clinical efficacy. When RE < 1, the drug 
decreases clinical efficacy.
The resulting 95% CI estimates do not support the hy-
pothesis that there is a conclusive increase in clinical effi-
cacy from a statistical point of view.
The population attributable efficacy (PAtE) was ob-
tained as an absolute difference between the parameters 
across the total population and parameters of the unex-
posed group. The PAtE is similar to AtE, but, unlike the 
latter, characterizes the population component of efficacy 
and, therefore, depends on how broadly montelukast is 
used in the given population.
The PAtE was estimated at 0.0755 (7.55%) with Eq. (11):
-
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Thus, montelukast increases clinical efficacy in the to-
tal population by 7.55% when used as a component of 
anti-asthmatic therapy.
To evaluate the standard error of PAtE, a pooled pro-
portion estimate was obtained from Eq. (6) to be 0.8240.
Using Eq. (12), the standard error of PAtE was estima-
ted to be 0.0258 (2.58%).
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The 95% CI of PAtE was obtained from Eq. (13) to be 
2.49%-12.61%.
5
                                            StPAtECI PAtE    (13)
Thus, montelukast provides a 2.49–12.61%-time in-
crease in clinical efficacy of the anti-asthmatic regimen 
(95% CI).
The χ2-square test was also determined by formula 
(14):
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where i – the row number (from 1 to l), j – the column 
number (from 1 to c), Eij – the actual number of observa-
tions in cell ij, Аij – the expected number of observations 
in cell ij.
χ2 was obtained from Eq. (14) to be 29.91.
This method is most common for analyzing the con-
tingency table. At a significance level (probability) of 
p≤0.05, the critical point of the Pearson distribution (χ2-
square) was 3.84. The resulting value of 29.91 exceeds 
3.84, therefore, there is a statistical relationship between 
the addition of montelukast to the anti-asthmatic regimen 
and positive clinical effects.
But the Pearson criterion (χ2-square) gives reason to 
speak about the presence or absence of a statistical relati-
onship between the influencing factor and the upcoming 
event. The proposed concept of risk factors makes it pos-
sible to quantify statistical dependence.
Conclusions
The AtE, RE, and PAtE estimates were found to be statis-
tically significant. RE was 1.23; i.e., there is a 1.23-time 
increase in clinical efficacy. However, the lower limit of 
its 95% CI (0.21–2.24) was less than 1, indicating that RE 
is not statistically significant and there may be no positive 
clinical effect of montelukast in other patient samples. In 
the studied sample, montelukast considerably improved 
efficacy of the anti-asthmatic therapy. The favorable out-
come rates were 91.85% (95% CI 90.15–93.55%) in the 
exposed group and 74.85% (95% CI 72.49–77.21%) in 
the comparator group. Adding montelukast to an anti-ast-
hmatic regimen was found to increase its clinical efficacy 
in the retrospective study, but the conclusion needs fu-
rther verification. The presented methodology for deter-
mining the correlation of the clinical efficacy of the phar-
macotherapy regimen with the addition of a drug can be 
successfully applied in the future.
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